| Dokumendiregister | Ravimiamet |
| Viit | REP-1/5616-2 |
| Registreeritud | 24.10.2025 |
| Sünkroonitud | 27.10.2025 |
| Liik | Väljaminev kiri |
| Funktsioon | REP Euroopa Farmakopöaga seotud asjaajamine |
| Sari | REP-1 Euroopa Farmakopöa alane kirjavahetus |
| Toimik | REP-1/2025 |
| Juurdepääsupiirang | Avalik |
| Juurdepääsupiirang | |
| Adressaat | European Directorate for the Quality of Medicines & HealthCare |
| Saabumis/saatmisviis | European Directorate for the Quality of Medicines & HealthCare |
| Vastutaja | Signe Leito (RA, Peadirektori asetäitja valdkond, Labor) |
| Originaal | Ava uues aknas |
Addition of Anakinra monograph to the Work Programme of Group 6
page 1 / 3
Q1-4 (4393)
NPA: (55078) Type: (!/list-dropdown)
A10 - Estonia (EE)
Please choose: (55079) Type: (L/list-radio)
In favour of the addition of Anakinra monograph to the work programme
A1
If opposed to this addition to the work programme, please state why (55080) Type: (T/text-long)
-
page 2 / 3
If you are in favour of this addition, please indicate any other known manufacturers to be
contacted (with contact details if available) (55081) Type: (T/text-long)
n.a
Please share any information related to the criticality of anakinra in your country or any other remark:
(55082) Type: (T/text-long)
-
Powered by TCPDF (www.tcpdf.org)
page 3 / 3
| Nimi | K.p. | Δ | Viit | Tüüp | Org | Osapooled |
|---|---|---|---|---|---|---|
| Farmakopöa töökava asjus | 24.10.2025 | 3 | REP-1/5616-1 | Sissetulev kiri | ra | European Directorate for the Quality of Medicines & HealthCare |